Imidocarb API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Imidocarb API 27885-92-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Imidocarb. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Imidocarb
- Synonyms:
- 1,3-Bis(3-(2-imidazolin-2-yl)phenyl)harnstoff , 1,3-bis(3-(2-imidazolin-2-yl)phenyl)urea , Imidocarbe , Imidocarbo , Imidocarbum , N,N'-bis(3-(4,5-dihydro-1H-imidazol-2-yl)phenyl)urea
- Cas Number:
- 27885-92-3
- DrugBank number:
- DB11521
- Unique Ingredient Identifier:
- 8USS3K0VDH
General Description:
Imidocarb, identified by CAS number 27885-92-3, is a notable compound with significant therapeutic applications. Imidocarb is a urea derivative used in veterinary medicine as an antiprotozoal agent for the treatment of infection with Babesia and other parasites.
Classification:
Imidocarb belongs to the class of organic compounds known as n-phenylureas. These are compounds containing a N-phenylurea moiety, which is structurally characterized by a phenyl group linked to one nitrogen atom of a urea group, classified under the direct parent group N-phenylureas. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Benzene and substituted derivatives class, specifically within the N-phenylureas subclass.
Categories:
Imidocarb is categorized under the following therapeutic classes: Amides, Amines, Anilides, Aniline Compounds, Anti-Infective Agents, Antiparasitic Agents, Antiprotozoals, Benzene Derivatives, Carbanilides, Phenylurea Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Imidocarb is a type of Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
